Targeting mitochondria for cancer therapy

  title={Targeting mitochondria for cancer therapy},
  author={Simone Fulda and Lorenzo Galluzzi and Guido Kroemer},
  journal={Nature Reviews Drug Discovery},
Mitochondria are the cells' powerhouse, but also their suicidal weapon store. Dozens of lethal signal transduction pathways converge on mitochondria to cause the permeabilization of the mitochondrial outer membrane, leading to the cytosolic release of pro-apoptotic proteins and to the impairment of the bioenergetic functions of mitochondria. The mitochondrial metabolism of cancer cells is deregulated owing to the use of glycolytic intermediates, which are normally destined for oxidative… 

Mitochondria in cancer: why mitochondria are a good target for cancer therapy.

Mitochondria in cancer: in the aspects of tumorigenesis and targeted therapy

The roles of mitochondria in cancer with respect to mutations and apoptosis are elaborated and mitochondria-targeting strategies as cancer therapies to enhance the killing of cancer cells are discussed.

Targeting malignant mitochondria with therapeutic peptides.

This review discusses anticancer peptides that intersect with pathological changes in the mitochondrion, a key pharmacological target in cancer due to many of the differences that arise between malignant and healthy cells at the level of this ubiquitous organelle.

Mitochondria-targeted drug delivery system for cancer treatment

This comprehensive review focused on the mechanisms of mitochondrial targeting and a variety of strategies to realize the purpose of mitochondria targeting, including that based on the use of lipophilic cations, and mitochondrial targeting signal peptides (MTS) as well as cell-penetrating peptide (CPPs).

Targeting cancer cell mitochondria as a therapeutic approach: recent updates.

This review provides an update on recent development in the field of targeting mitochondria and novel compounds that impact mitochondria, glycolysis or both and key challenges in this research area are discussed.

Role of Mitochondria in Cancer Stem Cell Resistance

The whole mitochondrial cycle, from its biogenesis to its death, either by mitophagy or by apoptosis, can be targeted by different drugs to reduce mitochondrial fitness, allowing for a restored or increased sensitivity to chemotherapeutic drugs.

Stress‐Related Mitochondrial Components and Mitochondrial Genome as Targets of Anticancer Therapy

The achievements and perspectives in the elucidation of the molecular basis for developing mitochondrial‐targeted compounds as potential anticancer agents are reviewed, with special attention to mitochondrial DNA mutations and mitochondrial dysfunction.

Mitochondrial permeability transition as target of anticancer drugs.

Observations of the effects of peniocerol (PEN), a sterol isolated from the root of Myrtillocactus geometrizans, at cellular and mitochondrial level evidence that PEN may trigger both the caspase-dependent and caspasesindependent apoptotic pathways, which renders PEN a very interesting compound that could be developed to obtain more effective antiproliferative agents targeting mitochondria for anticancer therapy.

Mitochondrial dysfunction in breast cancer

This review summarizes the mechanisms that protect the mitochondria of cancer cells against oxidative stress and identifies several transcription factors linked to the mitochondrial unfolded protein response (UPR mt).

Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules.

Several targeting strategies aimed at delivering useful cargo to mitochondria, including the use of delocalized lipophilic cations coupled to useful molecules, or peptides that insert in mitochondrial membranes are reviewed.



Mitochondria as therapeutic targets for cancer chemotherapy

A variety of experimental therapeutic agents can directly target mitochondria, causing apoptosis induction, and it is possible to design molecules that neutralize inhibitor of apoptosis proteins (IAPs) or heat shock protein 70 (HSP70).

Targeting Mitochondria with Organelle‐Specific Compounds: Strategies and Applications

Mitochondria are the energy factories of the cell and also serve as a checkpoint regulating programmed cell death. Not surprisingly, dysfunctional mitochondria are implicated in a variety of diseases

Mitochondrial gateways to cancer.

Mitochondria as targets for cancer chemotherapy.

Mitochondria in cancer cells: what is so special about them?

Selective targeting of bioactive compounds to mitochondria.

  • M. Murphy
  • Biology, Chemistry
    Trends in biotechnology
  • 1997

Disruption of the hexokinase–VDAC complex for tumor therapy

The plant hormone methyl jasmonate is shown to disrupt the interaction between human HK and VDAC, causing the inhibition of glycolysis and the induction of MOMP, and this finding may stimulate the development of a novel class of small anticancer compounds that inhibit the HK–VDAC interaction.

Mitochondrial Medicine: Pharmacological targeting of mitochondria in disease

This review discusses mitochondrial drug targeting strategies and a variety of novel mitochondrial drug targets including the electron transport chain, mitochondrial permeability transition, Bcl‐2 family proteins and mitochondrial DNA.